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 Abstract 
 Background: In obesity, which is a major contributor to insulin resistance and diabetes, the 
circulating level of S100A8/A9 (calprotectin) is elevated and declines after Roux-en-Y gastric 
bypass surgery (RYGB). However, studies on S100A8/A9 and the pathophysiological mecha-
nisms in insulin resistance and diabetes are few and contradictory.  Methods: We studied 48 
subjects who underwent RYGB, comprising a non-diabetic control group and two diabetic 
groups in whom diabetes either regressed or persisted, 6–12 months post-surgically. S100A8/
A9, interleukin 6 (IL-6) as well as other inflammatory and diabetes-related markers were mea-
sured pre- and post-surgically.  Results: Significant and similar decreases of BMI were found 
in all groups. S100A8/A9 and IL-6 decreased significantly in the group with diabetes remission 
and in the control group, but not in the group with persistent diabetes. The relative changes 
in S100A8/A9 and IL-6 correlated significantly (r = 0.905, p = 0.005) only in the group with 
persistent diabetes. In contrast, leukocyte count and C-reactive protein correlated significant-
ly to S100A8/A9 only in the control group.  Conclusion: Our study is suggestive of S100A8/A9 
and IL-6 being related to a persistent diabetes status post-surgically and of different patho-
physiological mechanisms being involved in the post-surgical changes in the three groups, 
despite similar decreases in BMI.  © 2017 The Author(s)
Published by S. Karger GmbH, Freiburg 
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 Introduction 
 Obesity is a major contributor to the development of insulin resistance, which in turn 
may lead to type 2 diabetes mellitus (T2DM)  [1] . The insulin resistance appears to be asso-
ciated with low-grade chronic inflammation, originating from adipose tissue  [1, 2] . Obesity-
associated chronic inflammation is characterized by an immense infiltration of macrophages 
in the adipose tissue  [1] with secretion of pro-inflammatory cytokines, such as interleukin 6 
(IL-6)  [2, 3] , and of peripheral leukocytosis  [4, 5] . 
 Leukocyte count and C-reactive protein (CRP) are increased in obesity and decline after 
bariatric surgery  [6, 7] . Further, elevated CRP is shown to be associated with metabolic 
syndrome  [8] and the risk of development of T2DM  [9] . Studies on IL-6 and T2DM have been 
conflicting, and the role of IL-6 in the development of insulin resistance and T2DM is contro-
versial  [1, 9–11] .
 S100A8/A9, a heterodimer of the two calcium-binding proteins S100A8 and S100A9, has 
been found elevated in a wide variety of inflammatory conditions. The main sources of 
S100A8/A9 are cells of myeloid origin, primarily neutrophils, monocytes, and early stages of 
macrophages  [12] . Furthermore, platelets contain and release S100A8/A9  [13] , and 
expression of S100A8 and S100A9 can be induced in epithelial cells under inflammatory 
conditions  [12] . S100A8/A9 has diverse intra- as well as extracellular functions and serves 
as a damage-associated molecular pattern (DAMP), being a ligand of Toll-like receptor 4 
(TLR-4). Interaction with TLR-4 results in production of pro-inflammatory cytokines, 
neutrophil adhesion to endothelium, and recruitment of neutrophils to sites of inflammation 
 [12] . 
 In obese mice in which leukocytosis is also seen, a recent study by Nagareddy et al.  [14] 
showed that S100A8/A9 and other TLR-4 ligands are upregulated in adipose tissue and 
interacts with TLR-4 on adipose tissue macrophages (ATMs). This interaction promotes the 
production of interleukin 1β (IL-1β) which in turn stimulates the bone marrow to produce 
monocytes and neutrophils. The monocytes infiltrate the adipose tissue, and thereby a vicious 
circle is induced.
 In humans, plasma S100A8/A9 levels have been found elevated in obese subjects  [15–
17] . However, in relation to insulin resistance and T2DM results are conflicting; one study did 
not find any correlation between circulating S100A8/A9 and markers of glucose metabolism 
 [15] , whereas other researchers have found S100A8/A9 to be correlated to insulin resistance 
 [16] and suggestive of being involved the development of insulin resistance  [17] .
 The aim of this study was to investigate the changes in the circulating level of S100A8/
A9 and the inflammatory markers CRP, IL-6, and leukocyte count after bariatric surgery in 
three phenotypically distinct groups in relation to glucose tolerance. We examined one group 
with diabetes both pre- and post-surgically, one group with diabetes pre-surgically but not 
post-surgically, and one group without diabetes before as well as after surgery. By choosing 
this approach, we attempt to distinguish between diabetes and obesity-related contributions 
to the inflammatory status.
 Material and Methods 
 Subjects 
 This study included subjects selected among the participants of the AdiKir Study Cohort, Hvidovre 
Hospital, Copenhagen  [18] . In brief, subjects suffering from severe obesity who underwent RYGB surgery 
were monitored clinically and para-clinically as well as pre- and post-surgically. 
 All participants had given written informed consent before participation, and the study was approved 
by the Scientific Ethics Committee of Capital Region of Denmark (HD-2009–78).
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 The selection was made among participants with leukocyte and platelet counts available. Further, in 
order to explore biochemically changes related to diabetes, the selection was based on diabetes status pre- 
and post-surgically. Subjects with an HbA1C  ≥ 48 mmol/mol or patient record information on antidiabetic 
therapy were defined as diabetics. 
 In total, 48 participants, comprising three subgroups according to diabetes status, were selected. The 
groups were named and composed as follows: T2DM–/–, a control group including 19 subjects with normal 
glucose tolerance pre- as well as post-surgically; T2DM+/–, comprising 19 diabetic subjects in whom diabetes 
remitted post-surgically; and T2DM+/+, consisting of 10 subjects who were diabetic prior to surgery and 
remained diabetic post-surgically.
 For each participant, anthropometric data and blood samples from two visits, one pre-surgically and 
one 612 months post-surgically, were chosen. 
 Sample Collection, Preparation and Storage 
 All samples were collected after an overnight fast. Plasma samples used for the analyses of S100A8/A9 
and IL-6 were collected in EDTA tubes and kept on ice until centrifugation, and serum was collected for the 
measurement of C-peptide and insulin. Both specimens were centrifuged at 2,500 ×  g at 4 ° C for 10 min and 
aliquoted into cryo tubes. All samples were processed within 2 h and kept at –20 °  C for maximum 1 week 
before storage at –80 °  C. During the same venipuncture, lithium-heparin plasma and EDTA blood were 
collected for analysis of CRP and leukocyte count, respectively. Finally, a venous and/or and capillary sample 
was collected for immediate measurement of glucose and HbA1C.
 Anthropometric Data 
 At each clinical visit the participants were weighed, and information on antidiabetic medication was 
collected. The height was measured at the first clinical visit.
 Biochemical Measurements  
 S100A8/A9 and IL-6 values were measured by use of enzyme-linked immuno-sorbent assays (ELISA). 
Samples from each of the three groups were run on separate plates with separate standard curves. Pre- and 
post-surgical samples from each participant were placed consecutively on each plate, and all samples were 
measured in duplicate. For each of the two analyses, assay kits of the same lot were used for all samples.
 S100A8/A9 was measured using the ‘Bühlmann MRP8/14 ELISA’ assay from Bühlmann Laboratories 
AG (Schönenbuch, Switzerland) with a limit of detection (LOD) of 400 μg/l and an intra- and inter-assay coef-
ficient of variation (CV) of 4.6% and 6.9% (at 1,400 μg/l), respectively. Duplicate measurements differing 
more than 20% were excluded. 19 (4 pre-surgically and 15 post-surgically) of the 96 measurements of 
P-S100A8/A9 were below LOD. In order not to lose information, we chose to assign all S100A8/A9 measure-
ments below LOD a value of 400 μg/l. 
 IL-6 was measured using the ‘Human IL-6 High Sensitivity ELISA’ assay from eBioscience Inc. (San 
Diego, CA, USA) with a LOD of 0.03 pg/l and intra-assay and inter-assay CV of 5.2% and 7.3 %, respectively. 
Duplicate measurements differing more than 12 % were excluded.
 C-peptide and insulin were analyzed on Immulite ® 2000 (Siemens Healthcare Diagnostics, Gwynedd, 
UK) with lowest reportable ranges of 33 pmol/l and 14.4 pmol/l, intra-assay CV of 2.3% and 5.5%, and inter-
assay CV of 2.9% and 7.3%, respectively  [19, 20] .
 CRP was analyzed on a Cobas 6000 ® , C501 (Roche Diagnostics, Rotkreutz, Switzerland) with a LOD of 
0.3 mg/l.
 CRP values of 16 (1 pre-surgically and 15 post-surgically) measurements were at or below LOD, and 
these were all assigned a value of 0.3 mg/l. 
 Leukocyte count was performed on a Sysmex XE-5000 TM (Sysmex Coorporation, Kobe, Japan). Glucose 
measurements were carried out on HemoCue ® Glucose 201+ (HemoCue AB, Ängelholm, Sweden) and 
reported as plasma equivalent values. HbA1C was analyzed on a Tosoh G7 (Tosoh Europe N.V, Tessenderlo, 
Belgium).
 Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as: (fasting serum 
insulin (mU/l) × fasting plasma glucose (mmol/l)) / 22.5  [21] . HOMA-IR is only reliable to use in T2DM not 
treated with insulin  [21] .
389Obes Facts 2017;10:386–395 
 DOI: 10.1159/000478097 
 Lylloff et al.: S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity 
and Diabetes before and after Roux-en-Y Gastric Bypass Surgery 
www.karger.com/ofa
© 2017 The Author(s). Published by S. Karger GmbH, Freiburg
 Statistics 
 Statistical analyses and graphics were performed with GraphPad Prism, Version 7.02 (GraphPad 
Software, San Diego, CA, USA). Data were tested for normality (Shapiro-Wilk Test). As most data were not 
normally distributed and due to the sample sizes, non-parametric statistics were chosen for all variables.
 The differences between pre- and post-surgical levels were assessed by Wilcoxon matched-pairs signed 
ranks test and Mann-Whitney test for paired and unpaired data. Comparisons of data between the three 
groups were made by Kruskal-Wallis Test. The correlations between variables were evaluated by Spearman 
rank test. 
 A p value of less than 0.05 was considered significant and all p values are two-sided. 
 In order to remove between-subject variation, relative decreases of the single variables were calculated 
as: (pre-surgical value – post-surgical value) / pre-surgical value.
 Due to missing data, the number of results included in each of the single analyses varies. The number of 
results is given in each table. 
 Results 
 Participant Characteristics and Study Visits 
 48 participants of both genders (31 females) with a median age of 49.7 (95% confidence 
interval (CI) of the median 46.1–52.3) years, at the pre-surgical blood sampling were included. 
 Table 1.  Pre- and post-surgical median levels of BMI, HOMA-IR and diabetes and inflammatory variables of the three groups
Group T2DM+/+ T2DM+/–  T2DM–/– p value
n median (95% CI levels) n median (95% CI levels) n median (95% CI levels)
Pre-surgically
BMI, kg/m2 10 42.3 (38.8–45.8) 19 42.9 (40.8–45.8) 19 42.3 (37.3–46.2) 0.645
HbA1C, mmol/mol 9 56 (49–86) a)**** c)* 19 45 (41–50) b)**** 19 37 (35–40) <0.0001
Glucose, mmol/l 9 8.6 (7.2–19.0) a)****c)** 17 6.3 (5.6–7.4) b)* 19 5.6 (5.1–6.0) 0.0002
C–peptide, pmol/l 10 843 (655–1,480) a)ns c)ns 19 1,258 (947–1,635) b)** 19 808 (682–1,291) 0.025
Insulin, pmol/l 4 117 (70–163) 18 145 (119–198) 19 105 (64–165) nd
HOMA-IR 4 6.75 (3.70–15.81) 16 6.28 (4.15–8.81) 19 3.76 (2.27–6.32) nd
S100A8/A9, μg/l 10 1,248 (701–1,972) 19 979 (649–1,195) 18 853 (630–1,204) 0.278
IL-6, ng/l 9 2.3 (1.5–3.9) 17 2.4 (2.0–3.4) 18 2.6 (2.1–3.4) 0.707
CRP, mg/l 9 3.0 (1.0–9.0) 19 5.0 (1.0–8.0) 19 6.0 (3.0–8.0) 0.642
Leukocyte count × 109/l 10 7.0 (4.5–11.6) 19 6.5 (5.8–7.2)) 19 6.0 (5.3–7.7) 0.456
Post-surgically
BMI, kg/m2 10 31.0 (27.6–34.6) 19 30.5 (29.2–33.6) 19 30.1 (26.8–31.7) 0.492
HbA1C, mmol/mol 10 48 (42–51) a)**** c)**** 19 37 (33–38) b)* 19 34 (32–36) <0.0001
Glucose, mmol/l 10 7.2 (5.5–9.5) a)*** c)** 18 5.2 (5.0–5.6) b)ns 19 5.0 (4.9–5.3) 0.0009
C–peptide, pmol/l 10 634 (473–798) 19 738 (516–847) 19 523 (417–645) 0.052
Insulin, pmol/l 9 43 (32–44) 19 53 (32–71) 17 43 (31–64) 0.317
HOMA-IR 9 1.70 (1.36–2.53) 18 1.76 (1.09–2.68) 17 1.33 (0.98–2.08) 0.312
S100A8/A9, μg/l 10 607 (400–863) 19 484 (400–710) 18 537 (400–691) 0.585
IL-6, ng/l 8 1.2 (0.8–5.0) 17 1.7 (1.2–2.4) 17 1.7 (1.2–2.9) 0.525
CRP, mg/l 10 0.7 (0.3–3.0) a)ns c)ns 19 1.0 (0.3–1.0) b)* 19 2.0 (1.0–4.0) 0.042
Leukocyte count × 109/l 10 6.3 (5.3–7.0) 19 6.0 (5.2–6.4) 19 5.6 (4.8–6.4) 0.497
 a)Significance levels of differences between T2DM+/+ and T2DM–/–.
b)Significance levels of differences between T2DM+/– and T2DM–/–.
c)Significance levels of differences betweenT2DM+/+ and T2DM+/–.
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001; ns = no significance; nd = not determined.
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Median time from the pre-surgical clinical visit and pre-surgical blood sampling to surgery 
were 97.5 (63–127) and 110.5 (84–137) days, respectively. Median time from surgery to the 
post-surgical clinical visit and post-surgical blood sampling were 207.0 (190–344) and 193.0 
(182–342) days, respectively.
 Median pre- and post-surgical BMI of all participants were 42.3 (40.8–44.5) and 30.5 
(29.4–31.7), kg/m 2 , respectively, and differed significantly (p < 0.0001). 
 Pharmacological anti-diabetic treatment included mono- or poly-therapy of metformin, 
sulunylurea, insulin analogues, glucagon-like petide-1 agonist and/or dipeptidyl peptidase-4 
inhibitors. Insulin analogues were administered pre-surgically in 7 post-surgically in 1 partic-
ipant, and samples were excluded for data analysis of insulin and HOMA-IR. 
 The median pre- and post-surgical levels and relative changes of diabetes and inflam-
matory variables of all participants are shown in supplementary table 1 (available at  http://
content.karger.com/ProdukteDB/produkte.asp?doi=478097) .
 Pre- and Post-Surgical Levels of BMI and Biochemical Variables  
 Pre- and post-surgical median levels of BMI and diabetes as well as inflammatory vari-
ables of the three groups are shown in  table 1 . 
 The median BMI did not differ between the three groups, neither pre- nor post-surgically. 
As expected, pre- as well as post-surgical HbA1C and plasma glucose levels differed signifi-
cantly between the three groups. Pre-surgical C-peptide levels differed significantly, while no 
difference was found post-surgically. Comparison of pre-surgical insulin and HOMA-IR levels 
of all groups were not done, due to the sample sizes. Post-surgically, no differences were 
found between the three groups.
 Pre-surgical CRP levels did not differ, whereas post-surgical levels differed significantly 
between the three groups. None of the other inflammatory markers showed any differences 
between the three groups, neither pre- nor post-surgically.
 HbA1C levels differed significantly between each of the groups, pre- as well as post-surgi-
cally. Pre-surgical plasma glucose levels differed significantly between each of the three 
groups, while the post-surgical plasma glucose level of T2DM+/+ was significantly higher 
than that of T2DM+/– and T2DM–/– and no difference was found between T2DM+/– and 
T2DM–/–. The pre-surgical C-peptide levels was significantly higher in T2DM+/– compared 
to T2DM–/–, whereas no differences were found between T2DM+/+ and T2DM–/– or 
T2DM+/+ and T2DM+/–. The post-surgical CRP level was significantly higher in T2DM–/– 
compared to T2DM+/–, while no significant differences were found between TD2DM+/+ and 
the other two groups.
 Absolute Changes 
 HbA1C, plasma glucose, C-peptide, S100A8/A9, and CRP decreased significantly in all 
three groups as shown in  figure 1 a,b. Insulin and HOMA-IR decreased significantly in T2DM+/– 
and T2DM–/–. As only 4 participants in T2DM+/+ were not treated with insulin, no comparison 
between pre- and post-surgical levels of insulin and HOMA-IR was performed in this group. 
IL-6 decreased significantly in T2DM+/–, while no significant changes were seen in T2DM–/– 
or T2DM+/+. Significant decreases of leukocyte counts were found in T2DM–/– and T2DM+/–, 
but not in T2DM+/+. 
 Relative Changes  
 In order to remove between-subject variation and thus make results comparable, the 
relative changes of each of the variables were calculated (supplementary table 2, available at 
 http://content.karger.com/ProdukteDB/produkte.asp?doi=478097 ). As shown in  figure 2 a, 
the relative decrease of HbA1C was significant in all groups and differed significantly between 
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 Fig. 1. Pre- and post-surgical me-
dian levels of diabetes and inflam-
matory variables. Median levels 
of diabetes ( a ) and inflammatory 
( b ) variables pre- (black) and 
post-surgically (grey). Boxes rep-
resent interquartile ranges and 
whiskers minimum and maxi-
mum values. Due to sample sizes 
comparisons of pre- and post-sur-
gical levels of insulin and HOMA-
IR of T2DM+/+ were not done. 
Significance levels of the differ-
ences between pre- and post-sur-
gical levels are indicated by  * p  ≤ 
0.05,  * * p  ≤ 0.01,  * * * p  ≤ 0.001 and 
 * * * * p  ≤ 0.0001, n.s. = no signifi-
cance. 
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 Fig. 2. Relative changes in diabe-
tes and inflammatory variables. 
Median levels of relative changes 
in diabetes ( a ) and inflammatory 
( b ) variables. Whiskers represent 
95% CIs of the medians. As 
S100A8/A9 and CRP values were 
truncated at values of 400 μg/l 
and 0.3 mg/l, respectively, the de-
creases of these variables are 
minimum decreases. Due to sam-
ple sizes comparisons to insulin 
and HOMA-IR of T2DM+/+ were 
not done. Significance levels of 
differences of the relative de-
creases between the single groups 
are indicated by  * p  ≤ 0.05,  * p  ≤ 
0.01,  * * * p  ≤ 0.001 and  * * * * p  ≤ 
0.0001, n.s. = no significance. 
393Obes Facts 2017;10:386–395 
 DOI: 10.1159/000478097 
 Lylloff et al.: S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity 
and Diabetes before and after Roux-en-Y Gastric Bypass Surgery 
www.karger.com/ofa
© 2017 The Author(s). Published by S. Karger GmbH, Freiburg
each of the groups. The relative decrease of plasma glucose did not reach significance in any 
of the groups. C-peptide decreased significantly in T2DM–/– and T2DM+/–, but not in 
T2DM+/+, and did not differ between T2DM–/– and T2DM+/–. Insulin decreased signifi-
cantly in T2DM+/– and T2DM–/–, but the difference between the two groups was not signif-
icant. 
 Significant decreases of S100A8/A9 and IL-6 were found in group T2DM+/– and T2DM–/–, 
but not in T2DM+/+ ( fig. 2 b). The decreases of S100A8/A9 and IL-6 did not differ between 
T2DM+/– and T2DM–/–. CRP decreased significantly in all three groups, but no differences 
were found between any of the groups. A significant decrease in leukocyte count was only 
found in T2DM+/–. 
 The correlations of the relative decreases in S100A8/A9 and those of BMI and diabetes 
and inflammatory variables are shown in  table 2 . 
 The relative decrease of S100A8/A9 was not correlated to BMI in any of the groups. A 
strong correlation between the relative decreases of S100A8/A9 and that of IL-6 in T2DM+/+, 
but not in T2DM+/– and T2DM–/–, was found. Interestingly, the correlation of the decrease 
in S100A8/A9 and that of CRP and leukocyte count progressed across the three groups being 
non-significant in T2DM+/+ and moderately to highly significant in group T2DM–/–. The 
relative decreases of IL-6 did not correlate significantly to neither inflammatory or diabetes 
variables, nor to BMI, in any of the groups (supplementary table 3, available at  http://content.
karger.com/ProdukteDB/produkte.asp?doi=478097 ).
 Discussion 
 In this study we explored changes in S100A8/A9 and other inflammatory markers after 
bariatric surgery in two phenotypically distinct diabetes groups compared to a non-diabetic 
control group before and after surgery.
 We found significant absolute decreases of S100A8/A9 and CRP in each of the groups, 
which is in accordance with previous studies on S100A8/A9, CRP, and weight loss  [6, 16, 17, 
22–24] and might reflect an overall decrease of the chronic low-grade inflammation seen in 
obesity. However, pre- and post-surgical levels showed rather large 95% CIs of all variables, 
especially those of the T2DM+/+ group. Therefore, we chose to focus on the relative changes.
 Table 2.  Spearman rank correlation coefficients of the relative decreases of S100A8/A9 to those of BMI, 
HOMA-IR and diabetes and inflammatory variables
T2DM+/+ T2DM+/–  T2DM–/–
n r (p value) n r (p value) n r (p value)
BMI 10 0.554 (0.101) 19 0.114 (0.643) 18 0.289 (0.244)
HbA1C 9 0.583 (0.108) 19 –0.179 (0.462) 18 0.636 (0.005)
Glucose 9 –0.003 (0.948) 16 –0.244 (0.359) 18 0.467 (0.050)
C-peptide 10 0.280 (0.432) 19 –0.224 (0.357) 18 0.399 (0.101)
Insulin 4 nd 18 –0.480 (0.044) 16 0.420 (0.106)
HOMA-IR 4 nd 15 –0.537 (0.041) 16 0.443 (0.086)
IL-6 8 0.905 (0.005) 16 0.407 (0.118) 16 0.06(0.816)
CRP 9 0.387 (0.302) 19 0.432 (0.064) 18 0.58 (0.010)
Leukocyte count 10 0.462 (0.180) 19 0.438 (0.061) 18 0.68 (0.002)
 Spearman rank correlations coefficients r (p value) of the relative decreases of S100A8/A9 to those of 
BMI, HOMA-IR and diabetes and inflammatory variables. Due to the sample sizes the correlations to insulin 
and HOMA-IR in T2DM+/+ were not done (nd). Significant correlations are shown in italics.
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 Our study showed that the relative decreases of S100A8/A9 and IL-6 were significant in 
T2DM–/– and T2DM+/–, but not in T2DM+/+. Further, a significant correlation between the 
decreases of S100A8/A9 and IL-6 in T2DM+/+ was seen. This was, despite similar weight loss, 
not the case in T2DM+/– and T2DM–/–, suggesting that a pathophysiological mechanism 
involving S100A8/A9 and IL-6 is related to a persistent diabetic status. The decreases of 
S100A8/A9 and CRP did not correlate in T2DM+/+, while in T2DM–/– significant correlations 
were found. The same trend was observed for changes in leukocyte count. Thus, these patterns 
of changes in inflammatory markers strongly indicate that the three groups are governed by 
different pathophysiological mechanisms.
 After surgery, improvements in both hepatic and peripheral insulin resistance have been 
reported  [25] . In the present study a marked improvement in insulin resistance was observed 
after surgery in T2DM+/– and T2DM–/–. In T2DM+/–, but not in T2DM–/–, a significant 
correlation between the relative decrease of S100A8/A9 and relative changes of HOMA-IR 
was observed. In T2DM+/+, the pre-surgical HOMA-IR could only be estimated in 4 partici-
pants not treated with insulin, but in this 4 participants the improvement in HOMA-IR seems 
to be similar to the changes in T2DM+/– and T2DM–/–. Taken all together, this might indicate 
that the changes in S100A8/A9 are not explained by improvement in insulin resistance alone, 
but are also related to diabetic state. Accordingly, the HOMA-IR did not differ between the 
three groups after surgery. 
 Studies in mice and humans have shown increased expression of S100A8 and S100A9 in 
adipose tissue of obese and diabetic subjects  [14, 17] , and the findings of Nagareddy et al.  [14] 
indicated that in mice S100A8/A9 is involved in a feed-forward loop that maintain a chronic 
inflammation of the adipose tissue. Our findings of significant post-surgical decreases in 
S100A8/A9 and correlations to leukocyte count and CRP in the control group are suggestive 
of an interruption of such a feed-forward loop. However, it does not explain the non-signif-
icant decreases of S100A8/A9 in T2DM+/+, in which the decrease of BMI did not differ from 
that of the two other groups. A previous study of Nagareddy et al.  [26] using a type 1 diabetic 
mice model, suggested that hyperglycemia promotes a S100A8/A9-driven myeolopoiesis. 
Taken this finding into account, the non-significant decreases of S100A8/A9 and leukocyte 
count in the diabetes-persistent group might actually be related to a persistent hypergly-
cemic state. This hypothesis is supported by the finding of Nakatsuji et al.  [27] that the circu-
lating level of S100A8/A9 in T2DM patients with abdominal obesity were reduced after 
3-month treatment with pioglitazone, which improves insulin sensitivity, without changes in 
BMI. 
 We did not find any correlation between the relative decreases of BMI and that of S100A8/
A9, further suggesting that changes in S100A8/A9 are not related to the weight loos induced 
by Roux-en-Y gastric bypass. This finding is in agreement with Nijhuis et al.  [22] who compared 
the decreases of S100A8/A9 and BMI. Ortega et al.  [16] and Catalan et al.  [17] have, on the 
other hand, detected weak to moderate correlations of circulating levels of S00A8/A9 and 
BMI. Thus, whether the decrease in S100A8/A9 is related to long-term changes in body 
composition or to immediate changes in anatomy or inflammatory or diabetes status is not 
clear. 
 In conclusion, our study is suggestive of S100A8/A9 and IL-6 being related to persistent 
diabetes post-surgically and of different pathophysiological mechanisms being involved in 
the three phenotypically different diabetes groups.
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